ArticleCancer cell2025
Commensal papillomavirus immunity preserves the homeostasis of highly mutated normal skin.
Abstract read
In one paragraph
Article in Cancer cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Beyond oncogenesis: the unexplored benefits of viruses in cancer immunity.Nature reviews. Cancer · 2026Review
- Virome antigens as triggers for immune recognition of mutant clones in normal tissues.JCI insight · 2026Article
- The human skin virome: Ecological dynamics, aberrant profiles, and therapeutic opportunities.Cell host & microbe · 2026Review
- Human LFA-1 governs T cell immune surveillance of the skin.Science immunology · 2026Article
- DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma.Cancer immunology research · 2025Article
- Resolution of Squamous-Cell Carcinoma by Restoring T-Cell Receptor Signaling.The New England journal of medicine · 2025Article
- Inciting commensal human papillomavirus immunity to combat cancer.Trends in cancer · 2025Article
- Current and Emerging Insights into the Causes, Immunopathogenesis, and Treatment of Cutaneous Squamous Cell Carcinoma.Cancers · 2025Review
- The Role of HPV in the Development of Cutaneous Squamous Cell Carcinoma-Friend or Foe?Cancers · 2025Review
- Allies in the epidermis.Nature reviews. Cancer · 2025Article
- Opinion: Commensal papillomavirus immunity preserves the homeostasis of highly mutated normal skin.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Heehwa G SonCenter for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Dat Thinh HaCenter for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USA.
Yun XiaCenter for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Tiancheng LiCenter for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Jasmine BlandinCenter for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Tomonori OkaCenter for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Marjan AzinCenter for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Danielle N ConradCenter for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Can ZhouCenter for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Yuhan ZengCenter for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Tatsuya HasegawaCenter for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
John D StrickleyCenter for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USA.
Jonathan L MesserschmidtCenter for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Ranya GuennounCenter for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Tal H ErlichCutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Gregory L ShoemakerCenter for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USA; Brown Cancer Center, University of Louisville Health Sciences Center, Louisville, KY, USA.
Luke H JohnsonCenter for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USA; Brown Cancer Center, University of Louisville Health Sciences Center, Louisville, KY, USA.
Kenneth E PalmerBrown Cancer Center, University of Louisville Health Sciences Center, Louisville, KY, USA; Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY, USA; Center for Predictive Medicine, University of Louisville Health Sciences Center, Louisville, KY, USA.
David E FisherCutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Thomas D HornDepartment of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Victor A NeelDepartment of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Rosalynn M NazarianDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Joongho J JohDepartment of Medicine, University of Louisville School of Medicine, Louisville, KY, USA; Brown Cancer Center, University of Louisville Health Sciences Center, Louisville, KY, USA.
Shadmehr DemehriCenter for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA; Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: sdemehri1@mgh.harvard.edu.
Funding
Transcriptional mechanisms and melanomaP01CA163222 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DAVID E FISHER · 2013 to 2026
$25.3MThe MITF transcriptional network: melanoma risk and carcinogenesisR01AR043369 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI DAVID E FISHER · 1996 to 2026
$9.4MTherapeutic strategies for treatment of giant congenital melanocytic neviR01AR072304 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI DAVID E FISHER · 2017 to 2026
$3.9MImmunity to commensal papillomaviruses for cancer therapyR01CA251755 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DEMEHRI, SHADMEHR, JOH, JOONGHO JOHN · 2021 to 2025
$2.6MImmunotherapy for Skin Cancer Precursors to Prevent Skin CancerR01AR076013 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI DEMEHRI, SHADMEHR · 2019 to 2023
$1.8MNCI NIH HHS P01 CA163222NCI NIH HHS R01 CA251755NIAMS NIH HHS R01 AR043369NIAMS NIH HHS R01 AR072304NIAMS NIH HHS R01 AR076013
Abstract
Immunosuppression commonly disrupts the homeostasis of mutated normal skin, leading to widespread skin dysplasia and field cancerization. However, the immune system's role in maintaining the normal state of mutated tissues remains uncertain. Herein, we demonstrate that T cell immunity to cutaneotropic papillomaviruses promotes the homeostasis of ultraviolet radiation-damaged skin. Mouse papillomavirus (MmuPV1) colonization blocks the expansion of mutant p53 clones in the epidermis in a CD8
Indexed as
PapillomaviridaePapillomavirus InfectionsSkinSkin NeoplasmsAnimalsCD8-Positive T-LymphocytesFemaleHomeostasisHumansKeratinocytesMiceMice, Inbred C57BLMutationTumor Suppressor Protein p53Ultraviolet RaysTumor Suppressor Protein p53aging skinCD8(+) T cell immunityclonal mutationcutaneotropic papillomavirusvirome
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.